SLC5A2 and hydrops fetalis: Future randomized trials should therefore incorporate dual-pathway designs testing IV iron plus SGLT2 inhibition in HFmrEF and HFpEF, stratify by biomarkers [46] such as hepcidin and NT-proBNP to identify responders, and assess hard outcomes including HF hospitalizations, cardiovascular mortality, and patient-reported quality of life.